Brolucizumab 12- and 16-Week Fixed Dosing Potential in Neovascular AMD: A post hoc Evaluation of Data from the HAWK and HARRIER Trials

Conclusions: This analysis demonstrates the potential durability of action and effectiveness of brolucizumab.

Source: Ophthalmologica - March 28, 2022 Category: Opthalmology Source Type: research